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Abstract 
 In recent years, inhibition of EGFR signaling has emerged as new 
treatment strategy for oral squamous cell carcinoma (OSCC). The EGFR–
directed inhibitor cetuximab is the only approved targeted therapy for the 
treatment of OSCC. The EGFR status may influence the response to cetuximab 
treatments. In this study, by analyzing the immunomarker for EGFR, we found 
that it indicated positivity in 58.3% of all cases we analyzed, and the 
invasiveness was inversely correlated with the expression of EGFR. We 
quantified the expression level of EGFR and analyzed the correlation between 
EGFR expression and cetuximab sensitivity using three different grade invasive 
human OSCC lines. The EGFR expression in high grade invasive cells was 
significantly down-regulated compared to low grade invasive cells. There was no 
significant anti-proliferative effect in high grade invasive cells treated with 
various concentrations of cetuximab. The EMT-associated genes N-cadherin, 
vimentin and Snail were up-regulated in high grade invasive cells. Low grade 
invasive cells displayed characteristics of typical epithelial cells, including 
expression of E-cadherin and absence of N-cadherin, vimentin and Snail. 
TGF-beta induced this low grade invasive cell to undergo an EMT-associated 
gene switch that results in low EGFR expression. These data suggested that 
loss of EGFR expression in OSCC was associated with EMT, and might have 
functional implications in tumor invasion and resistance to cetuximab treatments. 
 
Introduction 
 The epidermal growth factor receptor (EGFR/ErbB1/HER1) is 
overexpressed in a majority of OSCC tumors, and high expression levels have 
been associated with a more aggressive phenotype, poor prognosis, and 
resistance to cancer therapy (1). Multiple anti-EGFR antibodies (e.g., cetuximab 
and panitumumab) and small molecule tyrosine kinase inhibitors (e.g., gefitinib 
and erlotinib) targeting EGFR have been developed. However, so far, only the 
monoclonal antibody cetuximab (Erbitux®) has been approved for the treatment 
of advanced OSCC (2). Cetuximab treatment has been proven to be effective in 
recurrent or metastatic OSCC both as a first-line treatment in combination with 
platinum-based chemotherapy (3-6) and as a second-line treatment in patients 
with platinum-refractory disease (7-9). In clinical practice, EGFR expression is 
evaluated using a standardized immunohistochemistry (IHC) assay, designated 
to assess cell membrane staining. Recent IHC studies demonstrated EGFR 
overexpression in over three quarters of the analyzed OSCC cases, with values 
of 73.42% (10), 87.5% (11) and 72% (12). However, the cetuximab response 
rate is generally not higher than 20% (13), so the role of EGFR expression as a 
predictor of response to EGFR targeting agents remains unclear. 
 The sensitivity of some tumors to cetuximab can be explained by the 
presence of mutations in the EGFR tyrosine kinase domain (14, 15). However, 
such mutations are rare in OSCC (16). Thus, there is a need to elucidate the 
mechanisms underlying the differential drug response of cancer cells with wild 
type EGFR in order to identify those patients who could respond and clinically 
benefit from cetuximab and to develop new therapeutic strategies to circumvent 
the de novo or acquired resistance of tumors to cetuximab. Ideally, these 
resistance mechanisms would also be targetable and would thus provide a 
possibility to increase the efficacy of cetuximab treatment. The tumors are often 
therapy-resistant and may have their origin in tumor cells with an 
epithelial-mesenchymal transition (EMT) phenotype. EMT is a process whereby 
epithelial cells lose their polarity and cell-cell contact and acquire a migratory 
mesenchymal phenotype. EMT has also been shown to promote stem cell 
properties. Furthermore, the in vitro sensitivity of head and neck cancer cell lines 
to anticancer agents has been shown to be influenced by the expression of 
EMT-associated genes (17, 18). 
 In the present study, we evaluated the expression of EGFR in human 
OSCC tissues and cell lines and investigated their relationship to 
clinicopathological factors, and analyzed with regard to their EMT characteristics. 
OSCC cell lines were also examined for their intrinsic sensitivity to cetuximab 
treatments.  
 
Materials and methods 
Tissue samples. The present study was approved by the ethics committee of 
the Kanazawa University Graduate School of Medical Science and written 
informed consent had been obtained. The subjects were 24 patients with 
primary OSCC who underwent surgical resection at the Department of Oral and 
Maxillofacial Surgery at Kanazawa University Hospital between 1998 and 2008. 
The patients with carcinoma ranged from 43 years to 89 years old (64.4 ± 11.2 
years old, mean ± SD). The tumors’ TNM categories were classified according to 
the UICC (Union for International Cancer Control) system. The grade of tumor 
differentiation was determined according to the criteria proposed by the World 
Health Organization. The mode of tumor invasion was assessed according to 
the classification by Yamamoto et al. (19).  
 
Immunohistochemistry. Each specimen was fixed in 10% buffered formalin 
and then embedded in paraffin to prepare serial sections. Immunohistochemical 
staining was performed using EGFR pharmDx™ Kit (K1492, DAKO). The 
specificities of the staining were confirmed by using Universal Negative Control 
for IS-Series Rabbit Primary Antibodies (IS600, DAKO) instead of the primary 
antibody as a negative control. Three regions were image-captured under a light 
microscope at 100× magnification, and the images were evaluated based on 
number of stained tumor cells, following the method described by Bernardes et 
al. (20). EGFR expression was evaluated on the basis of extent of 
immunolabeling in tumor cell membranes and was classified on a four-point 
scale: 0 (no labeling, or labeling in < 10% of tumor cells); 1 (weak labeling, 
homogeneous or patchy, in > 10% of tumor cells); 2 (moderate labeling, 
homogeneous or patchy, in > 10% of tumor cells); 3 (intense labeling, 
homogeneous or patchy, in > 10% of tumor cells). These scores were 
subsequently grouped into two categories: low expression (0 or 1) and high 
expression (2 or 3). 
 
Cell lines. Three human oral squamous cell carcinoma cell lines established 
from tumor biopsies with different grade of invasive abilities were used: OSC-20 
(low grade invasive cells), OSC-19 (low grade invasive cells) and HOC313 (high 
grade invasive cells). OSC-20 is a cell line derived a 58-year-old female with 
tongue cancer metastatic to the cervical lymph nodes (21). OSC-19 was derived 
from a 61-year-old male with tongue cancer metastatic to the cervical lymph 
nodes (22). HOC313 was derived from a 51-year-old female with squamous cell 
carcinoma (involving the mandibular gingiva and oral floor) metastatic to the 
cervical lymph nodes (23). In addition, normal human dermal fibroblast cells 
(NHDF) were used as a control.  
 
Proliferation assay and cetuximab sensitivity. We used a 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay to test the 
ability of cetuximab to inhibit the proliferation of all three OSCC lines in vitro. 
First, 2500 cells per well were grown in DMEM medium (D7440, SIGMA) 
supplemented with 10% FBS in 96-well tissue culture plates. After 24 hours, the 
cells were treated with various concentrations of cetuximab (Erbitax®, Merck) (0, 
0.005 and 0.01 µg/ml) diluted in DMEM medium supplemented with 2% FBS. To 
measure the number of metabolically active cells after 24, 48 and 72 hour 
incubation, we used an MTT and quantified the results according to the 
manufacturer’s protocols. The optical density at 450 nm was measured using a 
microplate reader (iMark microplate reader, BioRad). 
 
RNA extraction, cDNA synthesis, and quantitative real-time PCR (qPCR). 
The mRNA expression levels of EGFR, E-cadherin, Vimentin, Twist, and Snail1 
were analyzed using a Rotor-Gene Q 2plex System (No.9001560, QIAGEN) with 
FAM/ZEN/IBFQ probes (DNA sequence was not opened, Integrated DNA 
Technologies, INC.). Total RNA was extracted with the RNeasy Protect Mini Kit 
(No.74124, Qiagen), and cDNA was obtained using PrimeScript 1st strand 
cDNA Synthesis Kit (code.6110A, TAKARA). All reactions and conditions 
followed the manufacturer’s instructions. We amplified 18S rRNA as an internal 
standard using HEX/ZEN/IBFQ probes (DNA sequence was not opened, 
Integrated DNA Technologies, INC.). Data were calculated using the 
comparative CT method, which presents the data as a fold difference in 
expression level relative to a calibrator sample; in this case, the mean 
expression of the three NHDFs. 
 
Enzyme-linked immunosorbent assay (ELISA). For enzyme-linked 
immunosorbent assay analysis of EGFR and phosphorylated EGFR, we cultured 
three human oral cancer cell lines (OSC-20, OSC-19 and HOC313). Cells were 
seeded into a 96-well tissue culture plate and fixed for 5 min by 4% 
formaldehyde solution in PBS after incubation for 24 hours. The expression of 
EGFR and phosphorylated EGFR was quantified using human EGFR In-Cell 
ELISA kit (ab126419, Abcam) according to the manufacturer’s protocols. The 
data are presented as a fold difference in expression level relative to the mean 
expression of the three NHDFs. 
 
Epithelial-mesenchymal transition (EMT) induction. To induce EMT, 
OSC-20 and OSC-19 cells were seeded at 70% confluence and cultured for 48 h 
and 72 h in Dulbecco’s modified Eagle’s medium with 0.5% fetal bovine serum. 
Recombinant human TGF-beta1 (240-B, R&D) was added to a final 
concentration of 5 ng/ml. 
 
Statistical analysis. Statistical analyses were conducted using JMP® 9.0 (SAS 
Institute, Inc., Cary, NC, USA). The relationships between the expression of 
EGFR proteins and clinicopathological parameters were examined by the 
Pearson’s chi-square test. The data of ELISA and MTT are presented as the 
mean values ± SEM. The differences between groups were tested for statistical 
significance using the two-tailed Mann-Whitney U test. Differences were 
considered significant at p< 0.05. 
 
Results 
Association between EGFR expression and clinicopathological features. 
EGFR were detected in the cell membrane and cytoplasm of tumor cells (Figure 
1). According to the criteria for EGFR immunohistochemical evaluation (20), 
58.3% (14/24) of all cases were positive. Table 1 displays the correlations 
between EGFR expression and the clinicopathological factors. The EGFR 
expression on the high grade invasive OSCC (4D in mode of invasion) was 
significantly down-regulated compared to low grade invasive OSCC (3 and 4C in 
mode of invasion) (p=0.039). On the other hand, EGFR expression was not 
correlated with tumor size (p=0.991), lymph node metastasis (p=0.456), local 
recurrence (p=0.071) or histological differentiation (p=0.137). 
 
EGFR expression in three different grade invasive OSCC cell lines. As 
demonstrated by immunohistochemical analysis, only invasiveness (mode of 
invasion) was inversely correlated with the expression of EGFR. Therefore, 
EGFR expression on three different grade invasive human OSCC lines (OSC-19, 
OSC-20 and HOC313) was analyzed at both the mRNA and the protein level by 
using quantitative real-time PCR and ELISA, respectively; data are presented as 
a fold difference relative to the mean of three NHDFs (normal human dermal 
fibroblast cells) (Figure 2). Among the three OSCC cell lines (OSC-19, OSC-20 
and HOC313), the EGFR mRNA expression level ranged from 3.7 to 0.74-fold 
higher compared to NHDF (Figure 2A). The expression of EGFR mRNA in two 
low grade invasive cells (OSC-20 and OSC-19) was 3.7 times and 2.3 times 
higher compared to NHDF, respectively. The EGFR mRNA expression in the 
high grade invasive cells (HOC313) was very low and almost similar to that of 
control normal cells. On the other hand, the two low grade invasive cells 
(OSC-20 and OSC-19) had an EGFR protein expression level 3.5-fold and 
2.1-fold higher than those of NHDF, respectively (Figure 2B). High grade 
invasive cells (HOC313) exhibited the lowest EGFR protein expression. The 
amounts of phosphorylated EGFR were assessed to determine the activation 
status of EGFR. Expression levels of phosphorylated EGFR ranged from 2.2 to 
0.87-fold higher compared to NHDF (Figure 2C). Expression patterns of 
phosphorylated EGFR were similar to patterns of mRNA and of EGFR protein. 
 
Cetuximab sensitivity of three different grade invasive OSCC cell lines. To 
evaluate the importance of EGFR status on cetuximab sensitivity, we further 
evaluated the cetuximab sensitivity of three human OSCC lines (OSC-19, 
OSC-20 and HOC313) with different grade of invasive abilities. Cells were 
seeded at clonal density, and the anti-proliferative effect of cetuximab was 
determined by MTT assay (Figure 3). Anti-proliferative effects of cetuximab were 
observed in OSC-20 and OSC-19 cell lines. In OSC-20 and OSC-19 cells (both 
are low grade invasive OSCC), after incubation for 48 and 72 hours in cetuximab 
0.005 µg/ml and 0.01 µg/ml, the proliferation was significantly inhibited 
compared to non-treated cells. However, there was no significant 
anti-proliferative effect in HOC313 cell lines (high grade invasive OSCC) treated 
with various concentrations of cetuximab. 
 
EMT phenotype on high grade invasive OSCC cell lines. To evaluate 
whether EGFR expression is associated with features of EMT, we tested levels 
of E-cadherin, N-cadherin, vimentin and Snail in three different grade invasive 
human OSCC lines (OSC-19, OSC-20 and HOC313) (Figure 4A). The 
expression levels of these EMT associated gene in the OSC-19 and HOC313 
are presented as fold differences relative to the OSC-20. The HOC313 (high 
grade invasive cells and loss of EGFR expression cells) displayed a 
mesenchymal phenotype manifested by loss of E-cadherin and acquisition of 
N-cadherin, vimentin and Snail compared to the OSC-20 and OSC-19 (Figure 
4A). To examine whether TGF-beta changes expression of the EMT associated 
gene and EGFR, two low grade invasive cells (OSC-20 and OSC-19) were 
exposed to TGF-beta (Figure 4B). The expression levels are presented as fold 
differences relative to the control vehicle at 48 and 72 hours, respectively. Serial 
examination of EMT markers (loss of E-cadherin and upregulation of N-cadherin, 
vimentin and Snail) in a time course (48 and 72 hours) showed that TGF-beta 
treatment resulted in EMT on OSC-20 (Figure 4B). On the other hand, the 
TGF-beta was not effective in EMT induction on OSC-19 cells. Strikingly, total 
mRNA of EGFR of OSC-20 and OSC-19 cells was reduced after EMT induction 
by TGF-beta treatment.  
 
Discussion 
 The EGFR is an oncogene (a tyrosine-kinase receptor from the erbB 
family) identified in more than one malignancy, including breast cancer, prostate 
cancer, pulmonary cancer, bladder cancer and head and neck cancers (24). 
EGFR is overexpressed and appears to be the dominant control factor of the 
malignant phenotype in head and neck squamous cell carcinomas, through the 
adjustment of the molecules involved in invasive angiogenic and 
lymphangiogenic processes (10). By analyzing the immunomarker for EGFR in 
this study, we found that it indicated positivity in 58.3% of all cases analyzed. 
This data were consistent with previous reports (10-12). And, we demonstrated 
for the first time that invasiveness (mode of invasion) was inversely correlated 
with the expression of EGFR on OSCC patients. We also have shown loss of 
EGFR expression in high grade invasive OSCC line (HOC313 cell). These data 
suggested that loss of EGFR expression was associated with invasive 
phenotype of OSCC. This potential association will be investigated in future 
studies. 
 We analyzed the correlation between expression of EGFR and 
cetuximab sensitivity using three human OSCC lines (OSC-19, OSC-20 and 
HOC313) with different grade of invasive abilities. We found variability in the 
response of different cell lines to cetuximab treatment. Cetuximab suppressed 
cell growth by approximately 23% in the most sensitive cell line (OSC-20), but it 
had no effect on HOC313 cell lines. The OSC-20 cell line showed a substantial 
increase in EGFR mRNA and protein compared to HOC313 cell lines. 
Conversely, the HOC313 cell line, which is not effected by cetuximab treatment, 
was the one that had the lowest EGFR expression. When evaluating the 
influence of the EGFR expression on the cetuximab treatment response, there 
was a significant difference in EGFR expression between sensitive cells 
(OSC-20) and resistant cells (HOC313) (Figures 2 and 3). Resistant cell lines 
had lower expression levels of EGFR, suggesting that the cetuximab treatment 
response may depend on the expression status of EGFR. In addition, a high 
expression level of phosphorylated EGFR tended to correlate with cetuximab 
sensitivity, indicating a role for activated EGFR in cetuximab response. Indeed, 
several studies have suggested that cells are sensitive to EGFR inhibition only if 
they are dependent on EGFR activation, cell survival, and growth (25). In 
concordance with these results, the level of phosphorylated EGFR has been to 
predict gefitinib (an EGFR tyrosine kinase inhibitor) sensitivity in OSCC. 
 The response to EGFR-targeted agents is inversely correlated with 
epithelial mesenchymal transition (EMT) in multiple types of tumors without 
known EGFR mutations, including NSCLC, bladder, colorectal, pancreas and 
breast carcinomas (26-30). In this study, the EMT associated genes, N-cadherin, 
vimentin and Snail, were up-regulated in cetuximab resistant OSCC tumor cells 
(HOC313). We also demonstrated that TGF-beta induced low grade invasive 
OSCC cell lines (OSC-20) to undergo an EMT-associated gene switch that 
results in their loss of EGFR expression. These results indicated that the net 
effect of TGF-beta signaling was the loss of EGFR activity with a concomitant 
EMT-associated gene switch of tumor cells, thereby leading to a migratory 
mesenchymal phenotype. Further studies are necessary to elucidate the precise 
molecular mechanisms underlying this association between EMT and regulation 
of EGFR expression. 
 In this study, we demonstrated that EGFR status influenced the 
response to cetuximab treatments, and invasiveness and an EMT phenotype 
could be useful to predict EGFR status. EMT related changes in gene 
expression, e. g., upregulation of N-cadherin, vimentin and Snail have also been 
proposed as potential biomarkers for EGFR status and prediction of response to 
cetuximab treatment. Further in vivo studies are necessary to confirm these 
result using clinical samples.  
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Figure 1. Immunohistochemistry stain of EGFR in human OSCC tissues. (A) 
Positive immunoexpression of EGFR in OSCC. (B) The specificities of the 
staining were confirmed by using non-immune antibody instead of the primary 
antibody as a negative control. Scale bar, 100 µm. 
 
Figure 2. EGFR expression on three different grade invasive human OSCC 
lines. The OSC-19, OSC-20 and HOC313 cell lines were evaluated for 
differences regarding (A) EGFR mRNA, (B) EGFR protein and (C) 
phosphorylated EGFR expression. The data are presented as a fold difference 
in expression level relative to the mean expression of the three NHDFs. 
Horizontal lines represent median values.  
 
Figure 3. The cetuximab sensitivity of three different grade invasive human 
OSCC lines. OSC-20, OSC-19 and HOC313 cells were treated with various 
concentrations of cetuximab as indicated and the anti-proliferative effect of 
cetuximab was determined by MTT assay. Each data point represents the mean 
of three independent experiments. The vertical bars show standard deviations. 
Error bars correspond to SEM. *P<0.05. 
 
Figure 4. EGFR and EMT-associated genes expression on three different grade 
invasive human OSCC lines. (A) The high grade invasive OSCC cell line 
(HOC313) showed up-regulation of EMT-associated genes. Relative mRNA 
expression levels of EMT-associated genes: E-cadherin, N-cadherin, vimentin 
and Snail in OSC-20, OSC-19 and HOC313 cell lines. The expression levels in 
the OSC-19 and HOC313 are displayed here as fold differences relative to the 
OSC-20. (B) TGF-beta induced EMT-associated genes in low grade invasive 
OSCC cell line (OSC-20 and OSC-19). The cells were treated with human 
TGF-beta or control vehicle for 48 and 72 hours. Relative mRNA expression 
levels of EGFR and EMT-associated genes: E-cadherin, N-cadherin, vimentin 
and Snail in OSC-20 and OSC-19 cell lines. The expression levels are displayed 























? P value 
High (n=14) Low (n=10) 
T category  T1 3 2 
0.991 
? ?  T2 8 6 
? ?  T3  1 0 
? ?  T4 2 2 
N category  negative 13 7 
0.456 
? ?  positive 1 3 
Local reccurence  negative 10 4 
0.071 
? ?  positive 4 6 
Differentiation  Well 10 7 
0.137 ? ?  Moderately 3 0 
? ?  Poorly 1 3 
Mode of invasion  Grade 3 7 1 
*0.039 ? ?  Grade 4C 5 3 
? ?  Grade 4D 2 6 
?
? ? ?
*P< 0.05 
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